Review



serum samples for timp1  (Boster Bio)


Bioz Verified Symbol Boster Bio is a verified supplier
Bioz Manufacturer Symbol Boster Bio manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Boster Bio serum samples for timp1
    Figure 2 ELISA validation of three serum biomarkers using an independent cohort and their correlation with clinical indices. (A–C) A cohort of 80 serum samples: 30 healthy controls (HC, green) and 50 patients with lupus nephritis (LN, red) were tested by ELISA for the levels of ICAM2, <t>TIMP1</t> and THBS1. (D) The discriminatory abilities of the three serum markers were assessed in distinguishing patients with LN from HCs using receiver operating characteristic (ROC) curve analysis. (E–K) The correlation of ELISA-assayed serum ICAM2 levels with clinical indices in LN. r denotes Spearman’s correlation coefficient. ****p<0.0001. AUC, area under the curve.
    Serum Samples For Timp1, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 128 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/serum+samples+for+timp1/pm40274316-68-0-29?v=Boster+Bio
    Average 94 stars, based on 128 article reviews
    serum samples for timp1 - by Bioz Stars, 2026-07
    94/100 stars

    Images

    1) Product Images from "Proteomics uncovers ICAM2 (CD102) as a novel serum biomarker of proliferative lupus nephritis."

    Article Title: Proteomics uncovers ICAM2 (CD102) as a novel serum biomarker of proliferative lupus nephritis.

    Journal: Lupus science & medicine

    doi: 10.1136/lupus-2024-001446

    Figure 2 ELISA validation of three serum biomarkers using an independent cohort and their correlation with clinical indices. (A–C) A cohort of 80 serum samples: 30 healthy controls (HC, green) and 50 patients with lupus nephritis (LN, red) were tested by ELISA for the levels of ICAM2, TIMP1 and THBS1. (D) The discriminatory abilities of the three serum markers were assessed in distinguishing patients with LN from HCs using receiver operating characteristic (ROC) curve analysis. (E–K) The correlation of ELISA-assayed serum ICAM2 levels with clinical indices in LN. r denotes Spearman’s correlation coefficient. ****p<0.0001. AUC, area under the curve.
    Figure Legend Snippet: Figure 2 ELISA validation of three serum biomarkers using an independent cohort and their correlation with clinical indices. (A–C) A cohort of 80 serum samples: 30 healthy controls (HC, green) and 50 patients with lupus nephritis (LN, red) were tested by ELISA for the levels of ICAM2, TIMP1 and THBS1. (D) The discriminatory abilities of the three serum markers were assessed in distinguishing patients with LN from HCs using receiver operating characteristic (ROC) curve analysis. (E–K) The correlation of ELISA-assayed serum ICAM2 levels with clinical indices in LN. r denotes Spearman’s correlation coefficient. ****p<0.0001. AUC, area under the curve.

    Techniques Used: Enzyme-linked Immunosorbent Assay, Biomarker Discovery



    Similar Products

    serum samples for timp1  (Cusabio)
    91
    Cusabio serum samples for timp1
    Figure 2 ELISA validation of three serum biomarkers using an independent cohort and their correlation with clinical indices. (A–C) A cohort of 80 serum samples: 30 healthy controls (HC, green) and 50 patients with lupus nephritis (LN, red) were tested by ELISA for the levels of ICAM2, <t>TIMP1</t> and THBS1. (D) The discriminatory abilities of the three serum markers were assessed in distinguishing patients with LN from HCs using receiver operating characteristic (ROC) curve analysis. (E–K) The correlation of ELISA-assayed serum ICAM2 levels with clinical indices in LN. r denotes Spearman’s correlation coefficient. ****p<0.0001. AUC, area under the curve.
    Serum Samples For Timp1, supplied by Cusabio, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/serum+samples+for+timp1/pm40274316-68-0-4?v=Cusabio
    Average 91 stars, based on 1 article reviews
    serum samples for timp1 - by Bioz Stars, 2026-07
    91/100 stars
    		  Buy from Supplier
    serum samples for timp1  (Boster Bio)
    94
    Boster Bio serum samples for timp1
    Figure 2 ELISA validation of three serum biomarkers using an independent cohort and their correlation with clinical indices. (A–C) A cohort of 80 serum samples: 30 healthy controls (HC, green) and 50 patients with lupus nephritis (LN, red) were tested by ELISA for the levels of ICAM2, <t>TIMP1</t> and THBS1. (D) The discriminatory abilities of the three serum markers were assessed in distinguishing patients with LN from HCs using receiver operating characteristic (ROC) curve analysis. (E–K) The correlation of ELISA-assayed serum ICAM2 levels with clinical indices in LN. r denotes Spearman’s correlation coefficient. ****p<0.0001. AUC, area under the curve.
    Serum Samples For Timp1, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/serum+samples+for+timp1/pm40274316-68-0-29?v=Boster+Bio
    Average 94 stars, based on 1 article reviews
    serum samples for timp1 - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 2 ELISA validation of three serum biomarkers using an independent cohort and their correlation with clinical indices. (A–C) A cohort of 80 serum samples: 30 healthy controls (HC, green) and 50 patients with lupus nephritis (LN, red) were tested by ELISA for the levels of ICAM2, TIMP1 and THBS1. (D) The discriminatory abilities of the three serum markers were assessed in distinguishing patients with LN from HCs using receiver operating characteristic (ROC) curve analysis. (E–K) The correlation of ELISA-assayed serum ICAM2 levels with clinical indices in LN. r denotes Spearman’s correlation coefficient. ****p<0.0001. AUC, area under the curve.

    Journal: Lupus science & medicine

    Article Title: Proteomics uncovers ICAM2 (CD102) as a novel serum biomarker of proliferative lupus nephritis.

    doi: 10.1136/lupus-2024-001446

    Figure Lengend Snippet: Figure 2 ELISA validation of three serum biomarkers using an independent cohort and their correlation with clinical indices. (A–C) A cohort of 80 serum samples: 30 healthy controls (HC, green) and 50 patients with lupus nephritis (LN, red) were tested by ELISA for the levels of ICAM2, TIMP1 and THBS1. (D) The discriminatory abilities of the three serum markers were assessed in distinguishing patients with LN from HCs using receiver operating characteristic (ROC) curve analysis. (E–K) The correlation of ELISA-assayed serum ICAM2 levels with clinical indices in LN. r denotes Spearman’s correlation coefficient. ****p<0.0001. AUC, area under the curve.

    Article Snippet: Serum samples for TIMP1 (CUSABIO, Catalogue No CSB- E08003h, Wuhan, China) and THBS1 (CUSABIO, Catalogue No CSB- E08763h, Wuhan, China) were diluted 1:100 and 1:400, respectively, whereas the ICAM2 (BOSTER, Catalogue No EK0999, Peachtree Corners, Georgia) ELISA assays used serum at 1:5 dilution.

    Techniques: Enzyme-linked Immunosorbent Assay, Biomarker Discovery

    Figure 2 ELISA validation of three serum biomarkers using an independent cohort and their correlation with clinical indices. (A–C) A cohort of 80 serum samples: 30 healthy controls (HC, green) and 50 patients with lupus nephritis (LN, red) were tested by ELISA for the levels of ICAM2, TIMP1 and THBS1. (D) The discriminatory abilities of the three serum markers were assessed in distinguishing patients with LN from HCs using receiver operating characteristic (ROC) curve analysis. (E–K) The correlation of ELISA-assayed serum ICAM2 levels with clinical indices in LN. r denotes Spearman’s correlation coefficient. ****p<0.0001. AUC, area under the curve.

    Journal: Lupus science & medicine

    Article Title: Proteomics uncovers ICAM2 (CD102) as a novel serum biomarker of proliferative lupus nephritis.

    doi: 10.1136/lupus-2024-001446

    Figure Lengend Snippet: Figure 2 ELISA validation of three serum biomarkers using an independent cohort and their correlation with clinical indices. (A–C) A cohort of 80 serum samples: 30 healthy controls (HC, green) and 50 patients with lupus nephritis (LN, red) were tested by ELISA for the levels of ICAM2, TIMP1 and THBS1. (D) The discriminatory abilities of the three serum markers were assessed in distinguishing patients with LN from HCs using receiver operating characteristic (ROC) curve analysis. (E–K) The correlation of ELISA-assayed serum ICAM2 levels with clinical indices in LN. r denotes Spearman’s correlation coefficient. ****p<0.0001. AUC, area under the curve.

    Article Snippet: Serum samples for TIMP1 (CUSABIO, Catalogue No CSB- E08003h, Wuhan, China) and THBS1 (CUSABIO, Catalogue No CSB- E08763h, Wuhan, China) were diluted 1:100 and 1:400, respectively, whereas the ICAM2 (BOSTER, Catalogue No EK0999, Peachtree Corners, Georgia) ELISA assays used serum at 1:5 dilution.

    Techniques: Enzyme-linked Immunosorbent Assay, Biomarker Discovery